Generate Biomedicines Inc.
Generate Biomedicines Inc. (GENB): 6 pipeline candidates · 2 upcoming catalysts · ~19 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
18.8 months
D/E 0.22 · 0% dilution
Lead: Phase 2
6 candidates
2 upcoming, next in ~897d
12 buys · 0 sells (180d)
A transparent, data-derived signal for Generate Biomedicines Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$160.6M
Quarterly Burn
$80.4M
Runway
18.8 mo
Revenue
$7.2M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
55
Total value held
$1.05B
| Holder | Shares | Value |
|---|---|---|
| flagship pioneering, llc | 62,673,117 | $783.4M |
| fmr llc | 4,217,524 | $52.7M |
| braidwell lp | 3,592,999 | $44.9M |
| arch venture management, llc | 1,944,426 | $24.3M |
| harbourvest partners llc | 1,722,210 | $21.5M |
| baker bros. advisors lp | 1,423,602 | $17.8M |
| harvard management co inc | 1,111,100 | $13.9M |
| nvidia corp | 833,325 | $10.4M |
| siren, l.l.c. | 736,104 | $9.2M |
| davern capital partners, lp | 591,800 | $7.4M |
Showing top 10 of 55 institutional holders of Generate Biomedicines Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Generate Biomedicines Inc.'s pipeline?
Generate Biomedicines Inc. (GENB) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Generate Biomedicines Inc.'s lead drug candidate?
Generate Biomedicines Inc.'s most advanced tracked candidate is enfortumab vedotin (Phase 1) for Advanced Urothelial Cancer.
What is Generate Biomedicines Inc.'s next catalyst?
Generate Biomedicines Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of G" — expected December 1, 2028.
What is Generate Biomedicines Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Generate Biomedicines Inc. has approximately 18.8 months of cash runway.
What is Generate Biomedicines Inc.'s market capitalization?
Generate Biomedicines Inc.'s market capitalization is approximately $1.7B.
Get the full picture on Generate Biomedicines Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.